18.97.14.90
dgid:
enl:
npi:0
/nas/content/live/oph360live/wp-content/themes/rd360/single.php
-Advertisement-
Retina
Retina Care 360

Study highlights visual and anatomical benefits of faricimab for nAMD

Posted on

A recent retrospective study evaluated the visual and anatomical outcomes of patients treated with faricimab intravitreal injections (IVI) for neovascular age-related macular degeneration (nAMD). The study included 170 eyes, both previously treated and treatment-naïve.

Key Findings:

Visual Acuity (VA):

  • Treatment-naïve eyes showed a greater improvement in best-corrected visual acuity (BCVA) after one (+5.00 letters) and three injections (+12.50 letters), though statistical significance was limited.
  • Previously treated eyes experienced modest gains in BCVA (+0.59 to +1.57 letters).
  • Eyes switching from aflibercept demonstrated a significant BCVA improvement (+2.15 letters after three injections).

Anatomical Improvements:

  • Central subfield thickness (CST) reduced significantly in all groups, particularly in treatment-naïve eyes (-94.10 μm after one injection).
  • Pigment epithelial detachment (PED) and retinal fluid metrics improved notably, especially in refractory cases.

Safety:

  • Ocular adverse events were reported in three cases. One patient experienced two stroke events during treatment.

Faricimab shows promise in enhancing visual and anatomical outcomes in nAMD, particularly in treatment-refractory cases.

Reference
Kunzmann BC, Schweig AS, Bartz-Schmidt KU, et al. Real-World-Data of Treatment-Naïve and Previously Treated Patients Receiving Up to 3 Injections of Faricimab in Neovascular Age-Related Macular Degeneration. Clin Ophthalmol. 2024;18:4029-4039. doi: 10.2147/OPTH.S482948. PMID: 39749039; PMCID: PMC11694016.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-